A single administration of gemtuzumab ozogamicin for molecular relapse of acute promyelocytic leukemia

Hematol J. 2004;5(3):279-80. doi: 10.1038/sj.thj.6200367.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aminoglycosides / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Gemtuzumab
  • Humans
  • Immunotoxins / therapeutic use*
  • Leukemia, Promyelocytic, Acute / drug therapy*
  • Leukemia, Promyelocytic, Acute / genetics
  • Leukemia, Promyelocytic, Acute / immunology*
  • Leukocyte Count
  • Male
  • Neoplasm, Residual / immunology
  • Reverse Transcriptase Polymerase Chain Reaction
  • Treatment Outcome
  • Tretinoin / therapeutic use

Substances

  • Aminoglycosides
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunotoxins
  • Tretinoin
  • Gemtuzumab